CareDx, Inc.
NASDAQ · us_market
No AI summary generated yet for this ticker.
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software. Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.
CAREDX (CDNA) shows a strong Mark Minervini-style setup with perfect moving average alignment, accelerating earnings (277.8% Q2Q), and a technical rating of 10, making it a high-growth momentum stock near its 52-week high.
CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions
CareDx, Inc. — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare...
Understanding CareDx’s recent share performance CareDx (CDNA) has drawn renewed attention after recent price moves, with the stock showing a return of 14.47% over the past month and 1.60% over the past 3 months, prompting closer scrutiny from investors. See our latest analysis for CareDx. Set against a 1 year total shareholder return of 38.17% and a 3 year total shareholder return of about 2.5x, the recent 7 day share price pullback and softer 1 day move suggest momentum has cooled after a...
BRISBANE, Calif. - CareDx, Inc. , - The Transplant Company - a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value...
CareDx, Inc. (CDNA) Q1 2026 Earnings Call April 28, 2026 4:30 PM EDTCompany ParticipantsCaroline Corner - Investor RelationsJohn Hanna - President, CEO...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14 of...
Q1 2026 Financial Results April 28, 2026 John Hanna President C Chief Executive Officer ...
Moby summary of CareDx, Inc's Q1 2026 earnings call
CareDx 2025 Environmental, Social, and Governance Report Table of Contents 01...
BTIG analyst Mark Massaro maintains CareDx (NASDAQ:CDNA) with a Buy and raises the price target from $26 to $28.
CareDx Inc (CDNA) reports a 39% revenue increase and raises 2026 guidance, while expanding into the oncology market with the acquisition of Naveris.
By Daniella Parra CareDx (Nasdaq: CDNA) said it signed a definitive agreement to acquire Naveris, a commercial-stage precision oncology diagnostics company, for up to $260 million and will close in the third quarter. Naveris makes NavDx, a blood-based test that monitors patients with HPV-driven cancers after treatment, the company said. “Naveris has developed and commercialized […]
CareDx (NASDAQ:CDNA) reported first-quarter 2026 results showing faster growth in its core testing and patient services businesses, while outlining two major portfolio moves: the pending divestiture of its lab products business and an agreement announced on the call date to acquire Naveris. Total r
Before we get started, I would like to remind everyone that management will be making statements during this call that include forward-looking statements. Any statements contained in this call that are not statements of historical facts should be deemed to be forward-looking statements. All forward-looking statements are based upon current estimates and various assumptions.
CareDx (CDNA) delivered earnings and revenue surprises of +209.09% and +7.31%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Presentation Operator MessageOperator Hello, everyone. Thank you for joining us, and welcome to CareDx Q1 2026 Financial Results Earnings Call. [Operator Instructions] I will now hand the
The US market regular session of Tuesday is over, let's have a look at the top gainers and losers in the after hours session today.
CareDx beat Q1 estimates with $117.7M revenue and raised 2026 guidance. Stock slipped 1.9% after hours despite strong testing services growth and strategic moves.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 2.76M | $47.92M | 0.00% | Added+0.8% | 2026-03-31 |
| ARKK | disruptive | 2.23M | $38.67M | 0.30% | Added+4.3% | 2026-03-31 |
| RenTech | quant | 1.18M | $20.56M | 0.03% | Added+7.2% | 2026-03-31 |
| DEShaw | quant | 874.9K | $15.19M | 0.01% | Trimmed-15.8% | 2026-03-31 |
| TwoSigma | quant | 231.6K | $4.02M | 0.00% | Added+159.4% | 2026-03-31 |
| FidelityFMR | fundamental | 231.3K | $4.02M | 0.00% | Added+10.5% | 2026-03-31 |
| Wellington | fundamental | 145.7K | $2.53M | 0.00% | Trimmed-14.2% | 2026-03-31 |
| TRowePrice | fundamental | 47.0K | $816 | 0.00% | Added+19.8% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-05upcoming | 0.23 | — | — |
| 2026-04-28 | 0.13 | 0.34 | +161.54% |
| 2026-02-24 | 0.23 | 0.12 | -47.06% |
| 2025-11-04 | 0.14 | 0.28 | +97.64% |
| 2025-08-06 | 0.12 | 0.10 | -18.03% |
| 2025-04-30 | 0.07 | 0.10 | +46.35% |
| 2025-02-26 | 0.15 | 0.18 | +22.03% |
| 2024-11-04 | 0.01 | 0.14 | +1099.66% |
| 2024-07-31 | -0.14 | 0.25 | +273.61% |
| 2024-05-09 | -0.21 | -0.03 | +85.44% |
| 2024-02-28 | -0.27 | -0.17 | +36.09% |
| 2023-11-08 | -0.40 | -0.18 | +54.55% |
| 2023-08-08 | -0.31 | -0.18 | +41.94% |
| 2023-05-10 | -0.10 | -0.11 | -7.84% |
| 2023-02-27 | -0.09 | -0.07 | +18.60% |
| 2022-11-03 | -0.14 | -0.06 | +57.14% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| CDNA | +6.14% | +21.38% | +21.13% | +34.31% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | +3.17% | +26.02% | +24.57% | +21.63% |